{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=27", "query": { "intervention": "Control Capsules", "page": 27 }, "page_size": 10 }, "pagination": { "page": 27, "page_size": 10, "total_count": 2901, "total_pages": 291, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=28&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=26&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T20:05:10.462Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01733017", "title": "Nutrition Intervention to Decrease Symptoms in Patients With Heart Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "Sodium reduction", "type": "BEHAVIORAL" }, { "name": "omega 3 and lycopene supplements", "type": "DIETARY_SUPPLEMENT" }, { "name": "rice bran oil capsules", "type": "DIETARY_SUPPLEMENT" }, { "name": "Generic dietary feedback from", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL", "DIETARY_SUPPLEMENT" ], "sponsor": "Terry Lennie", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 150, "start_date": "2011-11", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2017-03-17", "last_synced_at": "2026-10-25T20:05:10.462Z", "location_count": 2, "location_summary": "Lexington, Kentucky • Louisville, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01733017" }, { "nct_id": "NCT04001517", "title": "Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dementia With Lewy Bodies (DLB)" ], "interventions": [ { "name": "Neflamapimod", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EIP Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 91, "start_date": "2019-09-30", "completion_date": "2020-06-30", "has_results": true, "last_update_posted_date": "2023-06-29", "last_synced_at": "2026-10-25T20:05:10.462Z", "location_count": 22, "location_summary": "La Jolla, California • Santa Monica, California • Aurora, Colorado + 18 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04001517" }, { "nct_id": "NCT01116440", "title": "A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pelvic Pain Associated With Refractory Endometriosis" ], "interventions": [ { "name": "BGS649", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mereo BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "FEMALE", "summary": "18 Years to 49 Years · Female only" }, "enrollment_count": 27, "start_date": "2010-04-15", "completion_date": "2012-03-21", "has_results": true, "last_update_posted_date": "2020-11-23", "last_synced_at": "2026-10-25T20:05:10.462Z", "location_count": 42, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 36 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01116440" }, { "nct_id": "NCT00768989", "title": "Phase IIB Pilot of Atazanavir + Raltegravir", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Atazanavir", "type": "DRUG" }, { "name": "Raltegravir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Tenofovir/Emtricitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 167, "start_date": "2008-11", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2012-02-24", "last_synced_at": "2026-10-25T20:05:10.462Z", "location_count": 9, "location_summary": "Phoenix, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00768989" }, { "nct_id": "NCT00296491", "title": "Study Of Allergic Rhinitis In Patients Who Also Have Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "fluticasone propionate/salmeterol (FSC)", "type": "DRUG" }, { "name": "montelukast (MON)", "type": "DRUG" }, { "name": "fluticasone propionate (FP)", "type": "DRUG" }, { "name": "placebo nasal", "type": "DRUG" }, { "name": "ADVAIR DISKUS", "type": "DRUG" }, { "name": "placebo capsule", "type": "DRUG" }, { "name": "placebo DISKUS", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 725, "start_date": "2005-09", "completion_date": "2007-10", "has_results": true, "last_update_posted_date": "2016-12-16", "last_synced_at": "2026-10-25T20:05:10.462Z", "location_count": 104, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 88 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00296491" }, { "nct_id": "NCT01750281", "title": "Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV" ], "interventions": [ { "name": "Selumetinib 75 mg", "type": "DRUG" }, { "name": "Docetaxel 75 mg/m2", "type": "DRUG" }, { "name": "Docetaxel 60 mg/m2", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 212, "start_date": "2012-12-18", "completion_date": "2022-10-31", "has_results": true, "last_update_posted_date": "2023-10-24", "last_synced_at": "2026-10-25T20:05:10.462Z", "location_count": 13, "location_summary": "Santa Monica, California • Aurora, Colorado • Hollywood, Florida + 9 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01750281" }, { "nct_id": "NCT02255799", "title": "Multicenter Evaluation of Memory Remediation After TBI With Donepezil", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Traumatic Brain Injury", "Memory Deficits" ], "interventions": [ { "name": "Donepezil", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 75, "start_date": "2013-09-01", "completion_date": "2024-12-04", "has_results": false, "last_update_posted_date": "2025-01-15", "last_synced_at": "2026-10-25T20:05:10.462Z", "location_count": 4, "location_summary": "Indianapolis, Indiana • Charlestown, Massachusetts • Elkins Park, Pennsylvania + 1 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Charlestown", "state": "Massachusetts" }, { "city": "Elkins Park", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02255799" }, { "nct_id": "NCT05358821", "title": "28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Huntington Disease" ], "interventions": [ { "name": "SAGE-718", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Supernus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "25 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "25 Years to 65 Years" }, "enrollment_count": 69, "start_date": "2022-05-26", "completion_date": "2024-04-10", "has_results": true, "last_update_posted_date": "2025-09-15", "last_synced_at": "2026-10-25T20:05:10.462Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Los Alamitos, California • Englewood, Colorado + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05358821" }, { "nct_id": "NCT05619692", "title": "A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mild Cognitive Impairment", "Mild Dementia", "Alzheimer's Disease" ], "interventions": [ { "name": "SAGE-718", "type": "DRUG" }, { "name": "SAGE-718-matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Supernus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "50 Years to 80 Years" }, "enrollment_count": 174, "start_date": "2022-11-29", "completion_date": "2024-07-09", "has_results": true, "last_update_posted_date": "2025-09-15", "last_synced_at": "2026-10-25T20:05:10.462Z", "location_count": 37, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Lafayette, California + 34 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Lafayette", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Redlands", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05619692" }, { "nct_id": "NCT01674036", "title": "Safety, Tolerability and Pharmacokinetics of Genz-682452 in Healthy Men", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "Genz-682452", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "MALE", "summary": "18 Years to 45 Years · Male only" }, "enrollment_count": 63, "start_date": "2012-08", "completion_date": "2013-01", "has_results": false, "last_update_posted_date": "2014-03-19", "last_synced_at": "2026-10-25T20:05:10.462Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01674036" } ] }